On March 21, 2007, a federal judge in the U.S. District Court for the District of New Jersey found that Pfizer Inc.'s patents for celecoxib, the active ingredient in Celebrex®, for formulations containing celecoxib and for methods of treatment using celecoxib are valid and enforceable, and are infringed by Teva Pharmaceuticals U.S.A., Inc. Teva sought to produce and market a generic version of Pfizer's blockbuster drug Celebrex® for the treatment of osteoarthritis and rheumatoid arthritis. The Court found that Teva failed to prove obviousness, inequitable conduct, a violation of the best mode requirement, or obvious-type double patenting by clear and convincing evidence. Thus, the patents-in-suit are neither invalid nor unenforceable, and Teva has infringed the patents.
The Kaye Scholer team included Daniel L. Reisner, Jeffrey H. Horowitz, Abigail L. Langsam and Daniel Forchheimer, all in the Patent Litigation Department, and scientific advisors Anthony Khong and Karl Dresdner.
Also of Interest
- Shape of Things to Come: Protecting Product Configuration and Packaging Design September 26, 2016 • Articles
- On the Road to a Safe and Secure Internet of Things: What Companies Should Do September 19, 2016 • Articles
- Consumer Products: Adapting to Innovation Fall 2016 • Reports / Newsletters
- UNITED STATES: Trade Facilitation and Trade Enforcement Act of 2015 Strengthens... August 23, 2016 • Articles
- UNITED STATES: Phantom Mark Depicting Arrangement of Numerical Financial Data... August 23, 2016 • Articles
- Daily Journal Names Malecek Among the “Top 75 Intellectual Property Litigators” August 17, 2016 • Recognitions
- Best Lawyers 2017 Recognizes 41 Kaye Scholer Lawyers August 15, 2016 • Recognitions
- 3D Printing: New Life Sciences Technology and Old Product Liability Claims August 1, 2016 • Articles
- Kaye Scholer Secures Complete Motion to Dismiss for Redwood Capital July 22, 2016 • Client Successes